Skip Ribbon Commands
Skip to main content

Terumo Introduces Its Smallest, Lowest Prime Volume, Full-Size Adult* Capiox® Oxygenator

Innovative technology improves patient care during cardiopulmonary bypass

1/17/2019 - Ann Arbor, MICH.

​Terumo Cardiovascular Group, a global leader in cardiovascular surgery technologies, today announced the launch of its smallest full-size adult oxygenator, the Capiox® NX19 Oxygenator with UltraPrime™ Technology.

Terumo began sales of the product in the U.S. and Europe, and will expand its sales coverage to Japan and Asia.

Through Terumo's most advanced product design to date, the new Capiox NX19 oxygenator helps minimize the impact of cardiopulmonary bypass by reducing hemodilution, minimizing inflammatory response, and providing highly efficient gaseous microemboli (GME) removal.

"The Capiox NX19 oxygenator is the next step in Terumo's legacy of oxygenator innovation," said Robert DeRyke, President and CEO of Terumo Cardiovascular Group. "Terumo introduced the world's first hollow fiber oxygenator in 1982 and remains at the forefront of the industry, developing high quality products that help save patient lives."

New UltraPrime technology combines proprietary materials with engineering expertise to deliver a priming volume of just 185 mL and a maximum blood flow of up to 8 L/min. Evidence supports the use of lower prime circuits to reduce hemodilution, leading to fewer blood transfusions and lower risk of acute kidney injury (AKI).1

The Capiox NX19 oxygenator incorporates Terumo's new proprietary hollow fibers woven in a unique pattern to provide low prime and surface area reduction while delivering high gas exchange performance, all without increasing pressure drop.

A patent pending pre-heat-exchanger technology removes air before it enters the highly efficient heat exchanger. This in combination with Terumo's original self-venting technology and new Prime Assist feature ensures excellent GME removal.

  1. Ranucci M., Effects of Priming Volume Reduction on Allogeneic Red Blood Cell Transfusions and Renal Outcome After Heart Surgery. Perfusion. 2015; Vol 30(2) 120-126.
    * Full-size adult oxygenator with maximum flow range of 6-8 L/min.

About Terumo Cardiovascular Group

Terumo Cardiovascular Group manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass, intra-operative monitoring and vascular grafting. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Europe and Asia. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties. For more information, visit

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over US$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in interventional procedures, cardiovascular surgery, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use and also supplies drug delivery/injection devices to pharmaceutical firms. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

CAPIOX® is a registered trademark of Terumo Corporation. UltraPrime is a trademark of Terumo Cardiovascular Systems Corporation.


(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.